NCT05757466 2023-12-19
Prolgo-HL
St. Petersburg State Pavlov Medical University
Phase 2 Unknown
Clinical Trials
19 trialsNCT05979948 2023-09-14
CZ-WM01
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT05287984 2022-03-31
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04934930 2021-06-22
FLMRD
Meir Medical Center
Phase 2 Unknown
NCT04127916 2020-03-18
Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)
Samsung Medical Center
Unknown
NCT02747732 2019-04-23
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Phase 2 Unknown
NCT03315520 2018-05-22
BeEAC-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Phase 2 Unknown
NCT02836639 2016-07-19
BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
Pusan National University Hospital
Phase 2 Unknown
NCT02758925 2016-05-04
CyBeR-Lymph
University Hospital, Caen
Phase 2 Unknown
NCT02753062 2016-04-27
PTLD
Asan Medical Center
Phase 2 Unknown
NCT01412307 2015-08-11
LEBEN
GiovanniPascale
Phase 1/2 Unknown
NCT02423837 2015-04-22
BRiF
National Research Center for Hematology, Russia
Phase 3 Unknown
NCT02134262 2014-11-06
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Jichi Medical University
Phase 1/2 Unknown
NCT01884441 2014-01-29
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
Istituto Clinico Humanitas
Phase 2 Unknown
NCT01678430 2012-10-15
RIAltO
University of Liverpool
Phase 3 Unknown
NCT01657955 2012-08-06
CLL
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT01570049 2012-08-02
Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT01221103 2011-09-13
Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
Southern Europe New Drug Organization
Phase 1/2 Unknown
NCT00385125 2006-10-06
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
University of Magdeburg
Phase 2 Unknown